Mithridion wins key FDA drug designation
Mithridion Inc., a Madison drug development company focusing on treatments for Alzheimer’s disease and other central nervous system disorders, said Monday that it has been awarded Orphan Drug designation by the U.S. Food and Drug Administration for its lead drug candidate for the treatment of progressive supranuclear palsy. (MILWAUKEE BUSINESS JOURNAL, 5/10)
To access this post, you must purchase Premium Subscription - Daily Email and Full Website Access.